Shares of Alto Neuroscience, Inc. (NYSE:ANRO – Get Free Report) saw an uptick in trading volume on Wednesday. Approximately 1,292,736 shares were traded during trading, an increase of 215% from the previous session’s volume of 410,061 shares. The stock last traded at $21.9150 and had previously closed at $22.09.
Wall Street Analyst Weigh In
ANRO has been the subject of several recent analyst reports. HC Wainwright raised their target price on shares of Alto Neuroscience from $50.00 to $55.00 and gave the company a “buy” rating in a research note on Monday, August 17th. Wedbush upped their price target on Alto Neuroscience from $24.00 to $26.00 and gave the stock a “neutral” rating in a research report on Thursday, August 13th. BTIG Research increased their price objective on Alto Neuroscience from $28.00 to $37.00 and gave the company a “buy” rating in a report on Thursday, August 13th. Wall Street Zen cut Alto Neuroscience from a “hold” rating to a “sell” rating in a research report on Saturday, September 12th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Alto Neuroscience in a research note on Wednesday, July 29th. Eight investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Alto Neuroscience currently has an average rating of “Moderate Buy” and a consensus target price of $37.25.
Check Out Our Latest Research Report on Alto Neuroscience
Alto Neuroscience Price Performance
Alto Neuroscience (NYSE:ANRO – Get Free Report) last announced its quarterly earnings results on Wednesday, August 12th. The company reported ($0.65) earnings per share for the quarter, topping the consensus estimate of ($0.73) by $0.08. Equities analysts predict that Alto Neuroscience, Inc. will post -2.68 earnings per share for the current year.
Insider Buying and Selling at Alto Neuroscience
In related news, CFO Nicholas Smith sold 110,830 shares of the stock in a transaction on Tuesday, September 29th. The stock was sold at an average price of $26.58, for a total value of $2,945,861.40. Following the completion of the transaction, the chief financial officer directly owned 24,060 shares of the company’s stock, valued at approximately $639,514.80. This represents a 82.16% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 11.25% of the stock is currently owned by company insiders.
Institutional Investors Weigh In On Alto Neuroscience
Hedge funds have recently modified their holdings of the business. Quantinno Capital Management LP increased its stake in Alto Neuroscience by 1.4% during the first quarter. Quantinno Capital Management LP now owns 36,069 shares of the company’s stock worth $811,000 after acquiring an additional 490 shares during the last quarter. Farther Finance Advisors LLC lifted its position in Alto Neuroscience by 48,581.8% in the third quarter. Farther Finance Advisors LLC now owns 5,355 shares of the company’s stock valued at $137,000 after buying an additional 5,344 shares during the last quarter. Renaissance Technologies LLC lifted its position in Alto Neuroscience by 6.3% in the first quarter. Renaissance Technologies LLC now owns 103,499 shares of the company’s stock valued at $2,327,000 after buying an additional 6,100 shares during the last quarter. Dimensional Fund Advisors LP boosted its stake in Alto Neuroscience by 26.1% during the first quarter. Dimensional Fund Advisors LP now owns 39,324 shares of the company’s stock worth $884,000 after buying an additional 8,148 shares during the period. Finally, GK Wealth Management LLC purchased a new position in Alto Neuroscience during the second quarter worth about $226,000.
Alto Neuroscience Company Profile
Alto Neuroscience, Inc is a clinical-stage biopharmaceutical company focused on developing precision medicines for patients with psychiatric and neurological disorders. The company seeks to use neuroscience, digital health tools and biological and behavioral biomarkers to identify patient subgroups that may respond to specific treatments.
Alto’s pipeline has included investigational therapies for major depressive disorder and other central nervous system conditions. Its development programs are designed to address limitations of conventional psychiatric treatment by matching therapies to patient characteristics and measuring treatment response through objective data.
Featured Articles
- Five stocks we like better than Alto Neuroscience
- Tesla Wants to Make Its Own Chips—What Could Go Wrong?
- IREN Limited’s AI Pivot Gains Traction—But Can Its Data Centers Deliver?
- PBF Energy’s Stunning Rally Faces a Critical Test
- Citi Stock Falls Despite Earnings Beat: What Investors Need to Know
Receive News & Ratings for Alto Neuroscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alto Neuroscience and related companies with MarketBeat.com's FREE daily email newsletter.
